Yarrow Bioscience is offering 5,769,231 common shares at $26 each, generating $150,000,006.00 in gross proceeds and approximately $140.7 million net. The funds are intended for pipeline research and development, working capital, capital expenditures and other general corporate purposes, while underwriters can buy 865,384 additional shares.

Key Highlights

  • Net proceeds are estimated at approximately $140.7 million after Underwriting discounts, offering expenses and advisory fees.
  • Underwriters can purchase up to 865,384 additional common shares during a 30-day option period.
  • Yarrow Bioscience plans to use proceeds for pipeline research and development, Working Capital and capital expenditures.

Yarrow Bioscience, Inc. (NASDAQ: YARW) is offering 5,769,231 shares of common stock at $26.00 apiece, producing gross proceeds of $150,000,006. Estimated net proceeds are approximately $140.7 million after underwriting discounts, offering expenses and advisory fees. Share delivery was expected on or about September 14, 2026.

$150M Common-Stock Offering

The public offering price is $26.00 per share, while the underwriting discount and commission is $1.56 per share. That produces $9,000,000.36 in total underwriting discounts and commissions and leaves Yarrow Bioscience with $141,000,005.64 before offering expenses. Jefferies, TD Cowen and Guggenheim Securities are joint book-running managers. LifeSci Capital is the lead manager. The underwriters may offer the shares to certain dealers at a concession of no more than $0.936 per share, and the public offering price or dealer concession may later be reduced without changing the proceeds shown for Yarrow Bioscience. The company estimates other offering expenses at approximately $350,000. Certain underwriter expenses may be reimbursed by Yarrow Bioscience.

865,384-Share Additional-Share Option

The underwriters have a 30-day option to purchase up to 865,384 additional common shares from Yarrow Bioscience, in whole or in part. The option is exercisable at the public offering price less underwriting discounts and commissions. If exercised in full, the public offering price for the total shares would be $172,499,990. Underwriting discounts and commissions would reach $10,349,999.40, while proceeds to Yarrow Bioscience before expenses would total $162,149,990.60. Estimated net proceeds would be approximately $161.8 million if the underwriters purchase all additional shares.

Research And Corporate Funding

Yarrow Bioscience intends to combine the offering’s net proceeds with its existing cash, cash equivalents and investments. The company retains broad discretion over how it allocates the proceeds among those purposes. The stated funding plan covers both pipeline development and general corporate needs.

Post-Offering Share Count

The pro forma number of common shares outstanding immediately after the offering is 8,572,309. A further 2,688,931 shares were reserved for future issuance under the 2026 Stock Incentive Plan, while 336,116 shares were reserved under the 2026 Employee Stock Purchase Plan.